

DRUG NAME: Abemaciclib

SYNONYM(S): LY2835219¹

COMMON TRADE NAME(S): VERZENIO®

CLASSIFICATION: molecular targeted therapy

Special pediatric considerations are noted when applicable, otherwise adult provisions apply.

MECHANISM OF ACTION:

Abemaciclib is an orally administered, selective, reversible small-molecule inhibitor of cyclin-dependent kinases (CDK) 4 and 6. CDK 4/6 form complexes with cyclin D to promote phosphorylation of retinoblastoma (Rb) protein, which allows cell cycle progression. Abemaciclib is cell cycle phase-specific, blocking transition from the G1 to the S phase by binding to CDK 4/6 to inhibit Rb protein phosphorylation. Abemaciclib is an immunosuppressive agent.²⁻⁵

PHARMACOKINETICS:

Oral Absorption	absolute bioavailability = 45%; median T _{max} 8 hours (4.1 – 24 hours)	
Distribution	highly bound to serum albumin and alpha-1 acid glycoprotein	
	cross blood brain barrier?	yes
	volume of distribution ²	747 L
	plasma protein binding	96-98%
Metabolism	extensive hepatic metabolism primarily via CYP 3A4	
	active metabolite(s)	major: N-desethylabemaciclib (M2); minor: hydroxyabemaciclib (M20), hydroxy-N-desethylabemaciclib (M18)
	inactive metabolite(s)	M1 (oxidative metabolite)
Excretion	primarily as metabolites in feces	
	urine	3%
	feces	81%
	terminal half life ²	24.8 h
	clearance ²	21.8 L/h

Adapted from standard reference^{1,2,6} unless specified otherwise.

USES:

Primary uses:

*Breast cancer

*Health Canada approved indication

Other uses:

SPECIAL PRECAUTIONS:

Special populations:

- **East Asian patients** may experience a higher frequency of adverse events compared with Caucasian patients²
- **patients aged 65 years or older** may experience more hematologic adverse events, hypokalemia, hypocalcemia, and severe infections compared to younger patients²

Carcinogenicity: no information found

Mutagenicity: Not mutagenic in Ames test. Abemaciclib is not clastogenic in mammalian *in vitro* and *in vivo* chromosome tests.^{2,6}

Fertility: In animal studies, hypospermia and atrophy/degeneration/necrosis of the testis, epididymis, prostate and seminal vesicle were observed in male test subjects at doses up to two times that used in humans. No effects on female reproductive organs were observed.^{2,6}

Pregnancy: In animal studies, abemaciclib was teratogenic when administered during organogenesis at maternal exposures approximately equal to the expected human exposure following recommended doses. Findings included decreased fetal body weights and an increased incidence of cardiovascular and skeletal malformations and variations. For women of childbearing potential, pregnancy testing is recommended prior to initiating treatment. Contraception should be used during treatment and for at least three weeks after the last dose.^{2,6}

Breastfeeding is not recommended due to the potential secretion into breast milk. Do not breastfeed during treatment and for at least three weeks after the last dose.^{2,6}

SIDE EFFECTS:

The table includes adverse events that presented during drug treatment but may not necessarily have a causal relationship with the drug. Because clinical trials are conducted under very specific conditions, the adverse event rates observed may not reflect the rates observed in clinical practice. Adverse events are generally included if they were reported in more than 1% of patients in the product monograph or pivotal trials, and/or determined to be clinically important.^{7,8} When placebo-controlled trials are available, adverse events will generally be included if the incidence is $\geq 5\%$ higher in the treatment group. **Incidence data in the Side Effects table is based on abemaciclib monotherapy data where possible; in some cases, incidence data based on combination therapy has been included and is indicated with an asterisk (*).**

ORGAN SITE	SIDE EFFECT
Clinically important side effects are in <i>bold, italics</i>	
blood and lymphatic system/ febrile neutropenia	<i>anemia</i> (25%, severe 5%)
	febrile neutropenia (<1%) ⁹
	leukopenia (17%, severe 5%)
	<i>neutropenia</i> (37%, severe 24%); median onset to first episode = 29 days, median duration = 15 days
	<i>thrombocytopenia</i> (21%, severe 4%)
cardiac	palpitations (3%) ¹⁰
	sinus tachycardia (3%) ¹⁰
eye	lacrimation increase (8%)
	dry eye (5%)
gastrointestinal	<i>emetogenic potential: moderate</i> ¹¹
	abdominal pain (39%, severe 2%)
	constipation (17%, severe <1%)
	<i>diarrhea</i> (90%, severe 20%): see paragraph following Side Effects table
	dry mouth (14%)

ORGAN SITE	SIDE EFFECT
Clinically important side effects are in bold, italics	
	dyspepsia (8%)
	flatulence (5%)
	gastroesophageal reflux disease (5%)
	nausea (64%, severe 5%)
	stomatitis (14%)
	vomiting (35%, severe 2%)
general disorders and administration site conditions	chills (6%)
	fatigue (65%, severe 13%)
	pain (20%, severe 2%)
	peripheral edema (8%)
	pyrexia (11%)
infections and infestations	infections (31%, severe 7%) ⁶ ; fatal events have been reported
	upper respiratory tract infection (8%, severe <1%)
	urinary tract infection (8%)
investigations	ALT increase (7%, severe <1%); may require dose interruption/reduction/delay
	AST increase (8%, severe 2%); may require dose interruption/reduction/delay
	serum creatinine increase (13%, severe <1%); reversible, occurs during first 28 days of treatment
	weight decrease (14%)
metabolism and nutrition	appetite decrease (46%, severe 3%)
	dehydration (10%, severe 2%)
	hypokalemia (5%, severe 2%)
musculoskeletal and connective tissue	arthralgia (8%)
	back pain (11%, severe <1%)
	bone pain (7%, severe <1%)
	muscular weakness (7%, severe 2%)
	myalgia (5%)
	pain in extremity (5%)
nervous system	dizziness (11%)
	dysgeusia (12%)
	headache (21%)
	neuropathy (8%)
psychiatric	anxiety (5%)
	insomnia (5%)
respiratory, thoracic and	cough (19%)

ORGAN SITE	SIDE EFFECT
Clinically important side effects are in <i>bold, italics</i>	
mediastinal	dyspnea (14%, severe 3%)
	<i>interstitial lung disease/pneumonitis*</i> (2-5%, severe <1%); see paragraph following Side Effects table
	oropharyngeal pain (6%)
	rhinitis, allergic (5%)
	upper airway cough syndrome (5%)
renal and urinary	acute kidney injury (2%) ¹⁰
	chronic kidney disease (2%) ¹⁰
skin and subcutaneous tissue	alopecia (12%)
	dry skin (9%)
	pruritus (8%, severe <1%)
	rash (8%, severe 2%)
vascular	<i>venous thromboembolic events*</i> (5-6%, severe <1%); fatal events have been reported

Adapted from standard reference^{2,6,9} unless specified otherwise.

Diarrhea is reported in 90% of patients receiving monotherapy with abemaciclib and has been associated with dehydration and infection. Incidence is greatest during the first month of therapy. Median onset of first diarrhea is 7 days. For grade 2 and 3 diarrhea, median duration is 8 and 5 days, respectively. In the majority of events, symptoms resolve with supportive treatment and/or dose reductions. Start antidiarrheal therapy at the first sign of loose stools. Treatment interruption and subsequent dose reduction is recommended for grade 3 or 4 diarrhea, and for diarrhea that requires hospitalization.^{2,6}

Interstitial lung disease (ILD)/pneumonitis has been reported and can be life-threatening. Median time to onset is 8 months. Monitor patients for pulmonary symptoms which may include cough, dyspnea, hypoxia, or interstitial infiltrates on radiologic exam. Dose interruption and/or reduction is recommended for persistent or recurrent grade 2 ILD/pneumonitis. Permanently discontinue treatment for grade 3 or 4 ILD/pneumonitis.^{1,2,12}

INTERACTIONS:

AGENT	EFFECT	MECHANISM	MANAGEMENT
anastrozole, fulvestrant, letrozole, exemestane ^{2,3}	no effect on abemaciclib pharmacokinetics		
clarithromycin ²	2.2-fold increase in plasma exposure of abemaciclib and active metabolites	strong inhibition of CYP 3A4 by clarithromycin	avoid concurrent use; if coadministration cannot be avoided, abemaciclib dose reduction is indicated (see note for CYP 3A inhibitors below)
grapefruit juice ²	may increase plasma level of abemaciclib	may inhibit CYP 3A4 metabolism of abemaciclib in the intestinal wall	avoid grapefruit juice for 48 hours before and for duration of abemaciclib therapy

AGENT	EFFECT	MECHANISM	MANAGEMENT
ketoconazole ^{3,6}	<i>predicted</i> 16-fold increase in AUC of abemaciclib	strong inhibition of CYP 3A4 by ketoconazole	avoid concurrent use
loperamide ^{2,3}	no effect on abemaciclib pharmacokinetics		
metformin ^{2,6}	37% increase in AUC and 22% increase in C _{max} of metformin	inhibition of OCT2, MATE1 and MATE2-K transporters by abemaciclib	clinical significance unknown; monitor blood glucose levels
rifampin ²	77% decrease in AUC and 45% decrease in C _{max} of abemaciclib and active metabolites	strong induction of CYP 3A4 by rifampin	avoid concurrent use

Abemaciclib is a **substrate** of **CYP 3A**. **Inhibitors** of CYP 3A may increase the plasma concentration of abemaciclib and its metabolites. Monitor for increased abemaciclib toxicity when used concurrently. If possible, avoid coadministration with **strong** CYP 3A **inhibitors**. If coadministration cannot be avoided, consider abemaciclib dose reduction to 100 mg twice daily. Further dose reduction (to 50 mg twice daily) may be required in patients who have been dose reduced previously for adverse reactions.^{1-3,6}

CYP 3A inducers may decrease the plasma concentration of abemaciclib and its metabolites. Abemaciclib dose adjustment is not required for patients who require concomitant weak or moderate CYP 3A inducers. Avoid coadministration with **strong CYP 3A inducers**.^{2,6}

Abemaciclib inhibits Organic Cation Transporter 2 (**OCT2**) and Multidrug and Toxic Compound Extrusion Protein-1 and 2 (**MATE1 and MATE2-K**) transporters *in vitro*; clinical significance is unknown.^{2,3}

Abemaciclib is a substrate and inhibitor of P-glycoprotein (**P-gp**) and Breast Cancer Resistance Protein (**BCRP**) *in vitro*; clinical significance is unknown.^{2,3,6}

SUPPLY AND STORAGE:

Oral: Eli Lilly Canada Inc. supplies abemaciclib as 50 mg, 100 mg, 150 mg, and 200 mg film-coated tablets. Tablets contain lactose. Store at room temperature.²

DOSAGE GUIDELINES:

Refer to protocol by which patient is being treated. Numerous dosing schedules exist and depend on disease, response, and concomitant therapy. Guidelines for dosing also include consideration of absolute neutrophil count (ANC). Dosage may be reduced, delayed or discontinued in patients with bone marrow depression due to cytotoxic/radiation therapy or with other toxicities.

Adults:

BC Cancer usual dose noted in **bold, italics**

Oral^{2,4,9,13}: 150 mg (range 150 – 200 mg) PO twice daily

Administer with food or on an empty stomach.
Do not take with grapefruit or grapefruit juice.

Concurrent radiation: no information found

BC Cancer usual dose noted in **bold, italics**

<i>Dosage in myelosuppression:</i>	modify according to protocol by which patient is being treated
<i>Dosage in renal failure:</i>	creatinine clearance \geq 30 mL/min: no adjustment required ^{1,2} creatinine clearance < 30 mL/min: no information found
	calculated creatinine clearance = $\frac{N * (140 - \text{Age}) * \text{weight in kg}}{\text{serum creatinine in micromol/L}}$
	* For males N=1.23; for females N=1.04
<i>Dosage in hepatic failure:</i>	mild/moderate hepatic impairment (Child-Pugh class A or B): no adjustment required ^{2,6} severe hepatic impairment (Child-Pugh class C): reduce dosing frequency to once daily ^{1,6}
<i>Dosage in dialysis:</i>	no information found
<u>Children:</u>	safety and efficacy not established ²

REFERENCES:

1. Lexi-Drugs® - Lexicomp Online (database on the Internet). Abemaciclib. Wolters Kluwer Clinical Drug Information Inc., 27 December 2019. Available at: <http://online.lexi.com>. Accessed 23 January 2020.
2. Eli Lilly Canada Inc. VERZENIO® product monograph. Toronto, Ontario; 4 April 2019.
3. AHFS Drug Information® - Lexicomp Online (database on the Internet). Abemaciclib. Wolters Kluwer Clinical Drug Information Inc., 30 October 2019. Available at: <http://online.lexi.com>. Accessed 23 January 2020.
4. Sledge GW, Toi M, Neven P, et al. MONARCH 2: abemaciclib in combination with fulvestrant in women with HR+/HER2-advanced breast cancer who had progressed while receiving endocrine therapy. *J Clin Oncol* 2017;35(25):2875-2884.
5. Spring LM, Wander SA, Zangardi M, et al. CDK 4/6 inhibitors in breast cancer: current controversies and future directions. *Curr Oncol Rep* 2019;21(3):25.
6. Eli Lilly and Company. VERZENIO® full prescribing information. Indianapolis, IN, USA; September 2017.
7. Angela Chan MD. BC Cancer Agency Breast Tumour Group. Personal communication. 7 April 2020.
8. Khushminder Rai, Pharmacist. BC Cancer Agency Breast Tumour Group. Personal communication. 8 April 2020.
9. Dickler MN, Tolaney SM, Rugo HS, et al. MONARCH 1, a phase 2 study of abemaciclib, a CDK4 and CDK6 inhibitor, as a single agent, in patients with refractory HR+/HER2- metastatic breast cancer. *Clin Cancer Res* 2017;23(17):5218-5224.
10. Caroline Colozza. Eli Lilly Canada Medical Information. Personal communication. 18 February 2020.
11. BC Cancer. (SCNAUSEA) Guidelines for Prevention and Treatment of Chemotherapy-induced Nausea and Vomiting in Adults. Vancouver, British Columbia: BC Cancer; 1 Dec 2018.
12. FDA Medwatch. Ibrance (palbociclib), Kisqali (ribociclib), and Verzenio (abemaciclib): Drug safety communication - due to rare but severe lung inflammation. FDA US Food and Drug Administration, 13 September 2019. Available at: <http://www.fda.gov/Safety/MedWatch/default.htm>. Accessed 27 January 2020.
13. Goetz MP, Toi M, Campone M, et al. MONARCH 3: abemaciclib as initial therapy for advanced breast cancer. *J Clin Oncol* 2017;35(32):3638-3646.